RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q4 2023
Top Holdings64 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ROCKET PHARMACEUTICALS INC | 17.7M | $530.1M | 8.3% | $18.79 | +59.47% | 20 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 6.1M | $416.5M | 6.5% | $43.05 | +58.70% | 12 qtrssince 2021-Q1 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 6.8M | $397.7M | 6.2% | — | — | 20 qtrssince 2019-Q1 | Unchanged 0 |
AXSOME THERAPEUTICS INC | 4.5M | $357.3M | 5.6% | $61.42 | +29.59% | 20 qtrssince 2019-Q1 | Unchanged 0 |
ACADIA Pharmaceuticals Inc. | 11.3M | $352.3M | 5.5% | $18.32 | +70.94% | 7 qtrssince 2022-Q2 | Decreased 0 |
Ultragenyx Pharmaceutical, Inc. | 6.9M | $329.3M | 5.1% | $53.10 | -9.94% | 9 qtrssince 2021-Q4 | Increased 75 |
ALNYLAM PHARMACEUTICALS INC | 1.6M | $314M | 4.9% | $94.58 | +137.47% | 20 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE - ADR | 667,195 | $253.8M | 4.0% | $348.48 | +9.17% | 20 qtrssince 2019-Q1 | Increased 72 |
BRUKER CORP | 3.3M | $245.7M | 3.8% | $72.62 | +0.38% | 4 qtrssince 2023-Q1 | Decreased 0 |
CYTOKINETICS INC | 2.5M | $210.8M | 3.3% | $27.00 | +209.20% | 14 qtrssince 2020-Q3 | Decreased 0 |
PTC THERAPEUTICS INC | 7.4M | $204.6M | 3.2% | $43.39 | -36.48% | 20 qtrssince 2019-Q1 | Increased 58 |
MADRIGAL PHARMACEUTICALS INC | 815,191 | $188.6M | 2.9% | $219.14 | +5.59% | 3 qtrssince 2023-Q2 | Increased 84 |
ARVINAS INC | 4.2M | $173.4M | 2.7% | $41.16 | 0.00% | 1 qtr | New 79 |
MASIMO CORP | 1.5M | $171.4M | 2.7% | $174.28 | -32.75% | 20 qtrssince 2019-Q1 | Decreased 0 |
PENUMBRA INC | 662,664 | $166.7M | 2.6% | $262.94 | -4.33% | 10 qtrssince 2021-Q3 | Decreased 0 |
NATERA INC | 2.6M | $162.4M | 2.5% | $42.12 | +48.73% | 18 qtrssince 2019-Q3 | Decreased 0 |
Celldex Therapeutics, Inc. | 3.5M | $137.4M | 2.1% | $16.46 | +154.68% | 15 qtrssince 2020-Q2 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.3M | $121.9M | 1.9% | $22.38 | +2.44% | 18 qtrssince 2019-Q3 | Decreased 0 |
CARGO THERAPEUTICS INC | 5.2M | $119.8M | 1.9% | — | — | 1 qtr | New 69 |
VERICEL CORP | 3.2M | $114.4M | 1.8% | $17.89 | +99.09% | 20 qtrssince 2019-Q1 | Decreased 0 |
RTW INVESTMENTS, LP manages $6.4B across 64 positions as of Q4 2023. Top holdings: RCKT (8.3%), IMCR (6.5%), MRTX (6.2%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 14 new positions, 17 exits, 12 increased. Top move: MDGL (INCREASED, conviction 84). Portfolio: $6.4B across 64 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer